Prognostic factors among patients with brain metastases from cancer of unknown primary site

被引:3
作者
Padilla, C. Simoes [1 ]
Ho, V. K. Y. [1 ]
van der Strate, I. H. [1 ]
Leenders, W. P. J. [2 ]
de Vos, F. Y. F. L. [3 ]
van Zanten, S. E. M. Veldhuijzen [4 ]
Loef, C. [1 ]
机构
[1] Netherlands Comprehens Canc Org IKNL, Dept Res & Dev, Utrecht, Netherlands
[2] Predica Diagnost BV, Nijmegen, Netherlands
[3] Univ Utrecht, Univ Med Ctr, Canc Ctr, Dept Med Oncol, Utrecht, Netherlands
[4] Erasmus MC, Dept Radiol & Nucl Med, Rotterdam, Netherlands
关键词
CUP; Brain metastases; Cancer; Unknown primary; Survival; The Netherlands; SURVIVAL;
D O I
10.1007/s11060-022-04106-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Cancers of an unknown primary site (CUPs) have a dismal prognosis, and the situation is even worse for CUPs patients with brain metastases (BM-CUPs). This study aims to give better insight into the occurrence and survival of BM-CUPs patients. Methods Cases were selected from the Netherlands Cancer Registry (1,430 BM-CUPs/17,140 CUPs). Baseline characteristics between CUPs patients with and without BM were tested using chi-square tests and Mann-Whitney U tests. Patients' overall survival (OS) times were estimated by the Kaplan-Meier method and prognostic factors on OS was assessed using Cox proportional hazards regression analyses. Results The proportion of BM-CUPs patients among CUPs increased from 8% in 2009-2010 to 10% in 2017-2018 (p < 0.001). Most patients presented with multiple brain lesions (53%). Survival of BM-CUPs improved over time: one-year OS increased from 10% for patients diagnosed in 2009-2010 to 17% (2017- 2018) (p < 0.01), and median survival times increased from 1.8 months to 2.2 months. Independent predictors of poor survival were multiple (HR 1.25; p < 0.01) or unknown (HR 1.48; p < 0.01) locations of BM, unknown/poorly/undifferentiated carcinoma histology (HR 1.53; p < 0.01), or clinical symptoms of BM (HR 1.74; p < 0.01), accompanying liver metastasis (HR 1.43; p < 0.01) and more than one metastatic site outside the brain compared to none (HR 1.52; p < 0.01). Conclusion The incidence of patients with BM-CUPs is steadily increasing over time and overall prognosis remains dismal. Our results, however, show distinct patient subgroups that exhibit comparatively better outcomes, and more predictors may likely still be identified.
引用
收藏
页码:647 / 655
页数:9
相关论文
共 14 条
  • [1] Brain Metastasis from Unknown Primary Tumour: Moving from Old Retrospective Studies to Clinical Trials on Targeted Agents
    Balestrino, Roberta
    Ruda, Roberta
    Soffietti, Riccardo
    [J]. CANCERS, 2020, 12 (11) : 1 - 18
  • [2] Cancer of unknown primary-Epidemiological trends and relevance of comprehensive genomic profiling
    Binder, Carmen
    Matthes, Katarina Luise
    Korol, Dimitri
    Rohrmann, Sabine
    Moch, Holger
    [J]. CANCER MEDICINE, 2018, 7 (09): : 4814 - 4824
  • [3] Descriptive epidemiology of cancer of unknown primary in South Korea, 1999-2017
    Boo, Yoo-Kyung
    Park, Dayeon
    Lim, Jiwon
    Lim, Hyun-Sook
    Won, Young-Joo
    [J]. CANCER EPIDEMIOLOGY, 2021, 74
  • [4] Retrospective Analysis of Survival in Patients with Brain Metastases from an Unknown Primary Tumor
    Cirak, Musa
    Guclu, Dogan Gucluhan
    Akar, Emre
    Kazanci, Mehmet Hanifi
    Tural, Deniz
    [J]. TURKISH NEUROSURGERY, 2020, 30 (06) : 932 - 936
  • [5] Clinical Perspectives in Brain Metastasis
    Deshpande, Krutika
    Buchanan, Ian
    Martirosian, Vahan
    Neman, Josh
    [J]. COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2020, 10 (06):
  • [6] Survival outcomes following craniotomy for intracranial metastases from an unknown primary
    Gough, Melissa
    Nielsen, Molly
    Coulter, Ian C.
    Holliman, Damian
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (08) : 1475 - 1482
  • [7] Improved diagnosis, therapy and outcomes for patients with CUP
    Greco, F. Anthony
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (01) : 5 - 6
  • [8] Kok SJM., 2015, INT J CANC RES, V49, P12
  • [9] Carcinomas of an unknown primary origin-diagnosis and treatment
    Massard, Christophe
    Loriot, Yohann
    Fizazi, Karim
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (12) : 701 - 710
  • [10] NVMO, ZORGPAD PTO GESTART